Company
Avadel Pharmaceuticals plc
Headquarters: Dublin, Ireland
Founded: 1990
Employees: 66
CEO: Mr. Gregory J. Divis Jr.
Market Cap
$765.1 Million
USD as of Jan. 1, 2025
Avadel Pharmaceuticals plc Categories
Ireland Healthcare Drug Manufacturers—Specialty & GenericIreland Healthcare Ireland Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $138.2 M |
| EBITDA | $-62,007,000 |
| Gross Profit TTM | $127.0 M |
| Profit Margin | -52.53% |
| Operating Margin | -0.65% |
| Quarterly Revenue Growth | 613.20% |
Stocks & Indices
Avadel Pharmaceuticals plc has the following listings and related stock indices.
Stock: NASDAQ: AVDL wb_incandescent
Stock: FSX: AWK1 wb_incandescent
Key People
Gregory J. Divis (CEO, Director) Thomas S. Mc Hugh (Chief Financial Officer )